IMPROVE-IT预设分析:极低密度脂蛋白胆固醇水平的长期安全性与疗效
该研究为IMPROVE-IT试验的预设分析,纳入15 281例急性冠脉综合征患者,按1个月时达到的低密度脂蛋白胆固醇(LDL-C)水平分层,中位随访6年。达到LDL-C<30 mg/dL的患者与≥70 mg/dL者相比,9项预设安全事件无显著关联,主要疗效复合终点风险显著降低(调整后HR 0.79,95%CI 0.69-0.91,P=0.001)。
要点
- 1个月时LDL-C<30 mg/dL与9项预设安全事件无显著关联。
- LDL-C<30 mg/dL组主要疗效复合终点风险显著低于≥70 mg/dL组(调整后HR 0.79)。
- 极低LDL-C水平的长期安全性与疗效为强化降脂治疗提供依据。
核心结论
- 1个月时达到LDL-C<30 mg/dL的患者在6年期间安全性特征与较高LDL-C水平者相似,心血管事件发生率数值上最低。
- 这些数据为极高危患者继续强化降脂治疗以达到极低LDL-C水平的长期安全性和疗效提供了保证。
研究设计与样本
- IMPROVE-IT试验的预设分析,比较1个月时按达到的LDL-C水平分层的患者结局,并对基线特征进行校正,中位随访6年。
- 患者于2005年10月26日至2010年7月8日入组,数据分析于2014年12月至2017年2月进行。
- 共纳入15 281例患者,其中11 645例(76.2%)为男性,中位年龄63岁(四分位距56.6-70.7岁)。
主要发现
- 1个月时达到的LDL-C值<30 mg/dL、30-49 mg/dL、50-69 mg/dL和≥70 mg/dL的患者分别占6.4%、31%、36%和26%。
- LDL-C<30 mg/dL组(中位数25 mg/dL;四分位距21-27 mg/dL)更多被随机分配至依折麦布/辛伐他汀(85%),基线LDL-C更低,更可能年龄较大、男性、非白人、糖尿病、超重、未用过他汀、首次心肌梗死。
- 多因素校正后,达到的LDL-C水平与任何9项预设安全事件均无显著关联。
- 与LDL-C≥70 mg/dL组相比,LDL-C<30 mg/dL组主要疗效复合终点(心血管死亡、主要冠脉事件或卒中)的调整后风险显著降低(调整后HR 0.79;95%CI 0.69-0.91;P=0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In the Improved Reduction of Outcomes: Vytorin Efficacy International Trial, intensive low-density lipoprotein cholesterol (LDL-C)-reducing therapy with ezetimibe/simvastatin compared with simvastatin alone was associated with a significant reduction in cardiovascular events in 18 144 patients after acute coronary syndrome. The safety of very low LDL-C levels over the long-term is unknown. OBJECTIVE: To assess the safety and clinical efficacy of achieving a very low (<30 mg/dL) level of LDL-C at 1 month using data from the Improved Reduction of Outcomes: Vytorin Efficacy International Trial. DESIGN, SETTING, AND PARTICIPANTS: This prespecified analysis compared outcomes in patients stratified by achieved LDL-C level at 1 month in the Improved Reduction of Outcomes: Vytorin Efficacy International Trial and adjusted for baseline characteristics during 6 years' median follow-up. Patients were enrolled from October 26, 2005, to July 8, 2010, and the data analysis was conducted from December 2014 to February 2017. MAIN OUTCOMES AND MEASURES: Safety end points included adverse events leading to drug discontinuation; adverse muscle, hepatobiliary, and neurocognitive events; and hemorrhagic stroke, heart failure, cancer, and noncardiovascular death. Efficacy events were as specified in the overall trial. RESULTS: Among the 15 281 patients included in the study, 11 645 (76.2%) were men and the median age was 63 years (interquartile range, 56.6-70.7 years). In these patients without an event in the first month, the achieved LDL-C values at 1 month were less than 30 mg/dL, 30 to 49 mg/dL, 50 to 69 mg/dL, and 70 mg/dL or greater in 6.4%, 31%, 36%, and 26% of patients, respectively. Patients with LDL-C values less than 30 mg/dL (median, 25 mg/dL; interquartile range, 21-27 mg/dL) at 1 month were more likely randomized to ezetimibe/simvastatin (85%), had lower baseline LDL-C values, and were more likely older, male, nonwhite, diabetic, overweight, statin naive, and presenting with a first myocardial infarction. After multivariate adjustment, there was no significant association between the achieved LDL-C level and any of the 9 prespecified safety events. The adjusted risk of the primary efficacy composite of cardiovascular death, major coronary events, or stroke was significantly lower in patients achieving an LDL-C level less than 30 mg/dL at 1 month (adjusted hazard ratio, 0.79; 95% CI, 0.69-0.91; P = .001) compared with 70 mg/dL or greater. CONCLUSIONS AND RELEVANCE: Patients achieving an LDL-C level less than 30 mg/dL at 1 month had a similar safety profile (and numerically the lowest rate of cardiovascular events) over a 6-year period compared with patients achieving higher LDL-C concentrations. These data provide reassurance regarding the longer-term safety and efficacy of the continuation of intensive lipid-lowering therapy in very higher-risk patients resulting in very low LDL-C levels. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00202878.
引用
- Giugliano RP, Wiviott SD, Blazing MA, et al. Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial. JAMA Cardiol. 2017. PMID: 28291866. doi:10.1001/jamacardio.2017.0083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。